Zelira Therapeutics Limited (FRA:G1G)
Germany
· Delayed Price · Currency is EUR 0.1740
+0.0030 (1.75%)
At close: Dec 4, 2025
Zelira Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| Operating Revenue | 0 | 0.09 | 0.3 | 1.54 | 0.66 | Upgrade
|
| Revenue | 0 | 0.09 | 0.3 | 1.54 | 0.66 | Upgrade
|
| Revenue Growth (YoY) | -99.31% | -68.47% | -80.45% | 132.26% | - | Upgrade
|
| Cost of Revenue | 0.8 | 0.33 | 0.63 | 0.94 | 0.23 | Upgrade
|
| Gross Profit | -0.8 | -0.23 | -0.33 | 0.6 | 0.44 | Upgrade
|
| Selling, General & Admin | 1.67 | 2.33 | 5.89 | 7.39 | 5.85 | Upgrade
|
| Research & Development | 2.66 | 2.81 | 1.34 | 1.4 | 2.08 | Upgrade
|
| Other Operating Expenses | 0.1 | 0.01 | 0.12 | 0.23 | 0.11 | Upgrade
|
| Operating Expenses | 3.52 | 5.66 | 6.84 | 13.81 | 9.82 | Upgrade
|
| Operating Income | -4.32 | -5.9 | -7.16 | -13.21 | -9.38 | Upgrade
|
| Interest Expense | -0.41 | -0.74 | -0.08 | -0.05 | -0.04 | Upgrade
|
| Interest & Investment Income | - | 0 | 0 | 0.01 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.88 | 0.64 | 1.03 | 0.9 | 1.05 | Upgrade
|
| EBT Excluding Unusual Items | -3.85 | -5.99 | -6.21 | -12.35 | -8.37 | Upgrade
|
| Impairment of Goodwill | - | -30.75 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.06 | -0.07 | -0.18 | Upgrade
|
| Pretax Income | -3.85 | -36.74 | -6.27 | -12.41 | -8.55 | Upgrade
|
| Earnings From Continuing Operations | -3.85 | -36.74 | -6.27 | -12.41 | -8.55 | Upgrade
|
| Minority Interest in Earnings | 0.22 | 0.17 | 0.7 | 0.47 | - | Upgrade
|
| Net Income | -3.63 | -36.57 | -5.57 | -11.95 | -8.55 | Upgrade
|
| Net Income to Common | -3.63 | -36.57 | -5.57 | -11.95 | -8.55 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 10 | 8 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 10 | 8 | 7 | Upgrade
|
| Shares Change (YoY) | 1.20% | 12.70% | 25.19% | 21.25% | 36.81% | Upgrade
|
| EPS (Basic) | -0.32 | -3.22 | -0.55 | -1.49 | -1.29 | Upgrade
|
| EPS (Diluted) | -0.32 | -3.22 | -0.55 | -1.49 | -1.29 | Upgrade
|
| Free Cash Flow | -4.91 | -4.39 | -7.25 | -9.43 | -8.62 | Upgrade
|
| Free Cash Flow Per Share | -0.43 | -0.39 | -0.72 | -1.17 | -1.30 | Upgrade
|
| Gross Margin | - | -246.37% | -108.91% | 39.05% | 65.59% | Upgrade
|
| Operating Margin | -658713.11% | -6211.63% | -2379.17% | -857.21% | -1414.10% | Upgrade
|
| Profit Margin | -553029.27% | -38513.04% | -1850.75% | -775.36% | -1288.84% | Upgrade
|
| Free Cash Flow Margin | -747996.04% | -4621.90% | -2407.36% | -611.91% | -1299.02% | Upgrade
|
| EBITDA | -4.17 | -5.54 | -6.74 | -12.73 | -9.02 | Upgrade
|
| D&A For EBITDA | 0.15 | 0.35 | 0.42 | 0.47 | 0.36 | Upgrade
|
| EBIT | -4.32 | -5.9 | -7.16 | -13.21 | -9.38 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.